24.15
0.78%
-0.19
Jasper Therapeutics Inc stock is currently priced at $24.15, with a 24-hour trading volume of 25,590.
It has seen a -0.78% decreased in the last 24 hours and a +15.44% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $24.37 pivot point. If it approaches the $23.75 support level, significant changes may occur.
Previous Close:
$24.34
Open:
$24.4
24h Volume:
25,590
Market Cap:
$370.73M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-24.39
EPS:
-0.99
Net Cash Flow:
$-52.33M
1W Performance:
-1.51%
1M Performance:
+15.44%
6M Performance:
+4,839%
1Y Performance:
+1,428%
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
650 549 1400
Address
2200 Bridge Parkway, Suite 102, Redwood City
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-11-23 | Initiated | CapitalOne | Overweight |
Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
Nov-08-21 | Initiated | Credit Suisse | Outperform |
Oct-21-21 | Initiated | William Blair | Outperform |
Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress - StockTitan
StockTitan
O Dell Group LLC Decreases Holdings in Starbucks Co. (NASDAQ:SBUX) - Defense World
Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells $21,744.00 in Stock - MarketBeat
MarketBeat
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan - Yahoo Canada Shine On
Yahoo Canada Shine On
Jasper Therapeutics COO sells $21.7k in company stock By Investing.com - Investing.com
Investing.com
Jasper Therapeutics Announces Executive Changes and Stockholder Approvals By Investing.com - Investing.com
Investing.com
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Jasper Therapeutics Inc (JSPR) Net Income 2024
JSPR net income (TTM) was -$64.47 million for the quarter ending December 31, 2023, a -71.06% decrease year-over-year.
Jasper Therapeutics Inc (JSPR) Cash Flow 2024
JSPR recorded a free cash flow (TTM) of -$52.33 million for the quarter ending December 31, 2023, a -12.71% decrease year-over-year.
Jasper Therapeutics Inc (JSPR) Earnings per Share 2024
JSPR earnings per share (TTM) was -$6.1852 for the quarter ending December 31, 2023, a +39.95% growth year-over-year.
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Cap:
|
Volume (24h):